Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

RCT (n=157) found tevolocumab reduced LDL cholesterol level at week 24 vs.placebo (−2.0 vs. −0.2 mmol per litre) with mean percent change from baseline of −44.5% vs. −6.2% respectively; p<0.001) and other lipid variables in paediatric patients with familial hypercholesterolemia.

Source:

New England Journal of Medicine